Juan José Marugán
Research Subjects
Research Interests
Juan José Marugán has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Carl Crysler
Departments of Medicinal Chemistry, Structural Biology and Molecular Design and Informatics, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 665 Stockton Drive, Exton, PA 19341, USA
3 shared publicationsBeth Anaclerio
Johnson and Johnson Pharmaceutical Research & Development, L.L.C., 665 Stockton Drive, Suite 104, Exton, Pennsylvannia 19341
1 shared publicationBruce E. Tomczuk
Departments of Medicinal Chemistry, Structural Biology and Molecular Design and Informatics, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 665 Stockton Drive, Exton, PA 19341, USA
1 shared publicationBruce Tomczuk
Johnson and Johnson Pharmaceutical Research & Development, L.L.C., 665 Stockton Drive, Suite 104, Exton, Pennsylvannia 19341
1 shared publicationCarl L. Manthey
Departments of Medicinal Chemistry, Structural Biology and Molecular Design and Informatics, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 665 Stockton Drive, Exton, PA 19341, USA
1 shared publicationCarl Manthey
Johnson and Johnson Pharmaceutical Research & Development, L.L.C., 665 Stockton Drive, Suite 104, Exton, Pennsylvannia 19341
1 shared publication
Latest Publications
- 1 July 2006
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 41 (7) , 847-861
Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin
- 1 July 2006
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 41 (7) , 847-861
Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin
- 28 January 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (4) , 926-934
Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core
A novel series of potent and selective αvβ3/αvβ5 dualinhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhaced rigidity (i.e., (2-pyridylamino)propoxy versus the 2-(6-methylamino-2-pyridyl)ethoxy) led to improved activity toward αvβ3. Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole molecular core was replace with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure−activity relationships to obtain more potent αvβ3/αvβ5 dual antagonist with improved oral bioavailability.
- 28 January 2005
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (4) , 926-934
Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core
A novel series of potent and selective αvβ3/αvβ5 dualinhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhaced rigidity (i.e., (2-pyridylamino)propoxy versus the 2-(6-methylamino-2-pyridyl)ethoxy) led to improved activity toward αvβ3. Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole molecular core was replace with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure−activity relationships to obtain more potent αvβ3/αvβ5 dual antagonist with improved oral bioavailability.
- 1 September 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (17) , 4553-4555
Design, synthesis, and biochemical evaluation of novel αvβ3 integrin ligands
- 1 September 2004
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (17) , 4553-4555
Design, synthesis, and biochemical evaluation of novel αvβ3 integrin ligands